



International Consortium for Trials of Chemotherapeutic Agents in Tuberculosis (INTERTB)
St. George's, University of London,
Monday 13th November, 2023, Curve Lecture Theatre, Ground Floor.

[Microsoft Teams meeting](#)

Join on your computer, mobile app or room device

[Click here to join the meeting](#)

Meeting ID: 366 164 167 001

Passcode: 7uHBdm

[Download Teams](#) | [Join on the web](#)

AGENDA

08.30 – 09.00

REGISTRATION

Morning session – Professor Jon Friedland©

09.00 – 09.10.	Welcome to the Symposium	-	Jon Friedland©
09.10 – 09.25.	The Story So Far		Amina Jindani©
09.25 – 09.45	The RIFASHORT Persister Study		Mike Barer© Galina Mukamolova©
09.45 - 10.05.	Reflections on the outcomes of the Rifashort Trial		Rada Savic©
10.05 – 10- 25	Fifty years of rifampin - we're still figuring it out.		Charles Peloquin©
10.25 – 10.45	The Fast-TB Initiative		Andrew Vernon
10.45 - 11.00	The Global New TB Drug Pipeline		Barbara Laughon©

11.00 – 11.10 **DISCUSSION** **ALL**

11.10 – 11.45 **COFFEE**

11.45 – 12.05.	The PanAcea STEP2C Trial		Martin Boeree©
12.05 - 12.25.	The Truncate-TB Trial: how can we improve the strategy?		Nicholas Paton©
12.25 – 12.45.	Pretomanid for Tuberculosis (APT Trial)		Elisa Ignatius©
12.45 – 13.00	DISCUSSION		ALL

13.00 – 14.30 **LUNCH (Main Cafeteria)**

Afternoon session – Dr. Patrick Phillips©

14.30 – 14.50.	AI-Powered Mobile App Using Cough Analysis for TB Screening In 2 Minutes		Kitty Kolding©
14.50 - 15.10	Assessing efficacy of TB regimens in the presence of non-adherence: Are ITT and PP analyses fit for purpose?		Matthew Dodd©
15.10 – 15.30	Xpert cycle threshold as a marker of disease severity, implications for treatment stratification		Daniel Grint©
15.30 – 15. 50	TB Alliance Pipeline Update		Eugene Sun©
15.50 – 16.10	The WHO Target Regimen Profiles – closing the evidence and policy loop.		Gerry Davies©
16.10 – 16.30	Quo vadimus		Patrick Phillips©
16.30 – 17.00	DISCUSSION:		ALL

RECEPTION (Hyde Park Room)

© = confirmed